ClinicalTrials.gg
RecruitingNCT06778512Updated Jan 16, 2025

LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

An observational study in Lung, Lung Cancer and Cancer, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Observational

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.

Started
2019
with 1 other
Observational
8 of 26
6 open now
Primary completion
2026-12
later than 8 of 19 live
Registered
9th of 26
by date

Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is one of 2 that started in 2019, is one of 8 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 9th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.

03

Conditions studied

  • Lung
  • Lung Cancer
  • Cancer
  • NSCLC

Keywords

  • Lung cancer
  • Proteomics
  • Protein
  • NSCLC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with lung nodules confirmed by CT examination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signing of the form;
  2. Male or female, aged 18-75 years;
  3. Patients with lung nodules confirmed by CT examination;
  4. Good preoperative pulmonary function cooperation and complete reporting;
  5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
  6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.

Exclusion criteria

Exclusion Criteria:

  1. Poor preoperative pulmonary function cooperation or missing reports;
  2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
  3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
  4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
  5. Coexisting with other severe functional impairments;
  6. Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • OtherUsing tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t

    Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.

    Also known as: Draw peripheral blood, Obtain lesion tissue

06

What researchers measure

Primary outcomes

  1. Area Under the Curve

    AUC, or Area Under the Curve, is a commonly used metric in statistical and machine learning models, particularly for evaluating the performance of classification models. It refers to the area under the Receiver Operating Characteristic (ROC) curve, which plots the true positive rate (sensitivity) against the false positive rate (1-specificity) at various threshold settings. An AUC value ranges from 0 to 1, where: * 1 indicates a perfect model, * 0.5 suggests a model no better than random guessing, * \< 0.5 reflects a model performing worse than random. In clinical studies, AUC is often used to assess diagnostic tests, where a higher AUC indicates better test accuracy in distinguishing between conditions (e.g., disease vs. no disease).

    Time frame: 3 years

Secondary outcomes

  1. Differentially Expressed Proteins

    Differential proteins, or differentially expressed proteins (DEPs), refer to proteins that show significant changes in expression levels between different biological or experimental conditions, such as disease vs. healthy states, treated vs. untreated groups, or across time points in longitudinal studies. These proteins are identified through quantitative proteomics techniques, including mass spectrometry or label-free methods, and analyzed using statistical or bioinformatics tools to determine significance.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 90 months is above that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2025
First posted
Jan 16, 2025
StartActual
Jun 1, 2019
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 2026
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06778512
Responsible party
Jianxing He (Professor, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Jan 16, 2025
Start date
Jun 1, 2019
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 16, 2025

Study contacts

Jianxing He, Professor
Contact
drjiaxing.he@gmail.com
86-20-83337792

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion